CIRM Funded Clinical Trials
Selective, Off-the-Shelf Logic Gated CAR NK Cell Therapy Targeting CD33 and/or FLT3 Expressing Hematologic Malignancies
Disease Area:
Leukemia, Acute Myeloid (AML)
Trial Sponsor:
Senti Biosciences, Inc.
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
